Leukemia (AMS or MDS): A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With
Acute Myeloid Leukemia or Myelodysplastic Syndrome
Can the investigational drug, SY-1425 (tamibarotene) work in treating AML and MDS
in patients with a certain biomarker in their blood?
Basic Study Information
Purpose:Location: Cancer Center
The study includes three different groups. Two of these groups will receive SY-1425
alone. The other group will receive SY-1425 along with another drug called azacitidine.
Your study doctor will discuss the study with you to determine which group you will
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02807558?term=SY-1425-201&rank=1
Study Reference #: ILEU17032
Lead Researcher (Principal Investigator)
Lead Researcher: Jane Liesveld, MD
Study Contact InformationStudy Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Additional Study Details
Learn More About These Conditions
More information about Leukemia
More information about Myeloid leukemia, acute
Trial Not Found
The study you are looking for is not active at this time.
Return to Search